HC Wainwright Issues Pessimistic Forecast for Nyxoah (NASDAQ:NYXH) Stock Price

Nyxoah (NASDAQ:NYXH - Get Free Report) had its price target dropped by analysts at HC Wainwright from $17.00 to $15.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 96.08% from the company's current price. HC Wainwright also issued estimates for Nyxoah's Q1 2025 earnings at ($0.48) EPS, Q2 2025 earnings at ($0.53) EPS, Q3 2025 earnings at ($0.58) EPS, Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.25) EPS, FY2026 earnings at ($1.86) EPS and FY2027 earnings at ($0.58) EPS.

Separately, Stifel Nicolaus cut their target price on Nyxoah from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Friday, March 14th.

Nyxoah Stock Performance

NASDAQ NYXH traded down $0.35 during trading on Wednesday, hitting $7.65. 81,348 shares of the company's stock traded hands, compared to its average volume of 46,675. The business has a 50 day moving average of $10.35 and a 200-day moving average of $9.35. Nyxoah has a 12-month low of $6.76 and a 12-month high of $13.50. The company has a debt-to-equity ratio of 0.21, a quick ratio of 4.95 and a current ratio of 5.28. The stock has a market capitalization of $260.56 million, a price-to-earnings ratio of -4.09 and a beta of 1.42.

Remove Ads

Nyxoah (NASDAQ:NYXH - Get Free Report) last released its quarterly earnings data on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). The business had revenue of $1.35 million during the quarter, compared to analysts' expectations of $2.02 million. Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. As a group, equities research analysts anticipate that Nyxoah will post -1.91 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. LPL Financial LLC bought a new stake in Nyxoah during the fourth quarter valued at $102,000. Walleye Capital LLC raised its position in shares of Nyxoah by 23.9% during the 4th quarter. Walleye Capital LLC now owns 14,831 shares of the company's stock valued at $119,000 after buying an additional 2,862 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in shares of Nyxoah during the 4th quarter worth $135,000. Geode Capital Management LLC increased its stake in Nyxoah by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 17,100 shares of the company's stock valued at $137,000 after acquiring an additional 2,774 shares during the last quarter. Finally, Kovack Advisors Inc. raised its position in Nyxoah by 100.0% during the fourth quarter. Kovack Advisors Inc. now owns 20,000 shares of the company's stock valued at $160,000 after purchasing an additional 10,000 shares in the last quarter.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.